Goto, Shinji
Dr Shinji Goto has been working on discovering drug targets for calcific aortic valve disease at CICS since 2015.
Before joining CICS, he researched the development of a new PPARα agonist as a selective anti-hyperlipidemic drug at Tokyo New Drug Research Laboratories (Kowa Company, Ltd.). He received his Ph.D. in Pharmaceutical Science at Tohoku University in 2012. There, he studied cellular signaling mediated by thromboxane A2 receptor.
Publications
Show
Goto S, Rogers MA, Blaser MC, Higashi H, Lee LH, Schlotter F, Body SC, Aikawa M, Singh SA, Aikawa E
Standardization of Human Calcific Aortic Valve Disease in vitro Modeling Reveals Passage-Dependent Calcification.
Schlotter F, Halu A, Goto S, Blaser MC, Body SC, Lee LH, Higashi H, DeLaughter DM, Hutcheson JD, Vyas P, Pham T, Rogers MA, Sharma A, Seidman CE, Loscalzo J, Seidman JG, Aikawa M, Singh SA, Aikawa E
Spatiotemporal Multi-omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease.
Rogers M, Maldonado-Martinez N, Hutcheson JD, Goettsch C, Goto S, Yamada I, Faits T, Sesaki H, Aikawa M, Aikawa E
Dynamin-Related Protein 1 Inhibition Attenuates Cardiovascular Calcification in the Presence of Oxidative Stress.
Goto S, Saito M, Obara Y, Moriya T, Nakahata N
Involvement of lipid rafts in multiple signal transductions mediated by two isoforms of thromboxane A₂ receptor: dependency on receptor isoforms and downstream signaling types.
